Eli Lilly’s Stock Surge Aided by FDA Approval of New Weight-Loss Pill
Eli Lilly and Company (LLY) experienced a significant stock price increase of over 5% following the announcement that the U.S. Food and Drug Administration (FDA) has approved its new oral weight-loss medication known as Foundayo (orforglipron). According to Eli Lilly, this pill can be ingested at any time without the need for food or water restrictions.
This approval marks the beginning of intensified rivalry between Eli Lilly and Danish pharmaceutical firm Novo Nordisk (NVO), known for its own weight-loss drugs. In response to Eli Lilly’s announcement, Novo Nordisk’s stock declined by 1%.
Foundayo, intended for overweight adults and those with obesity, is set to be available from April 6, 2026, through U.S. retail pharmacies and telehealth providers. Eli Lilly’s CEO, David Ricks, described the product as "obesity care designed for the real world," highlighting its convenience as a once-daily pill that facilitates substantial weight loss.
In the growing market for weight-loss medications, Eli Lilly and Novo Nordisk have been vying for dominance. Novo Nordisk first captured attention with its GLP-1 drugs, Ozempic and Wegovy, but Eli Lilly’s recently launched Zepbound has quickly gained traction as well. The focus has shifted in the past two years from injectable versions to oral forms of medication, which present fewer barriers for patients.
Although Novo Nordisk’s Rybelsus was the first oral semaglutide treatment to receive FDA approval, it was primarily aimed at treating Type 2 diabetes and not specifically for weight loss. However, the company later introduced the Wegovy pill for weight management in December.
Despite injectable drugs traditionally being regarded as more effective, as shown by clinical trial outcomes, both Eli Lilly and Novo Nordisk are invested in developing pill formats.
Clinical trial results demonstrate that Eli Lilly’s Foundayo pill can lead to an average weight reduction of 11.1% for users. In comparison, the injectable Zepbound has shown superior results with users losing an average of approximately 20.2% of their body weight.
Conversely, Novo Nordisk’s Wegovy pill results indicate that participants lost about 14% of their body weight, while those using the injectable form reported an average weight loss of around 15%.
As both companies continue to innovate and adapt to consumer needs, the competition within the weight-loss drug market is likely to intensify.
For further updates and insights into US equities, follow Jake Conley on social media or contact him directly.
